Please find enclosed

September 30, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE: 543748 SYMBOL: AARTIPHARM Dear Sir/Madam, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI Listing Regulations”) This is in continuation to our previous communication dated September 02, 2026, regarding the disclosure made under Regulation 30 of the SEBI Listing Regulations. The Company had informed the Stock Exchanges about the receipt of an order dated August 29, 2026, from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat, levying stamp duty and penalties totaling Rs. 59,50,00,000/- (Rupees Fifty-Nine Crore Fifty Lakh only) in respect of the Scheme of Arrangement (Demerger) sanctioned by the Hon'ble NCLT, Ahmedabad Bench vide order dated September 21, 2022. Pursuant to Regulation 30(7) we wish to inform you that Aarti Pharmalabs Limited ("the Company") has filed a Writ Petition before the Hon'ble High Court of Gujarat at Ahmedabad challenging the said order dated August 29, 2026, passed by the Superintendent of Stamps, Gujarat Please take the same on your records. Thanking you, Yours faithfully, For AARTI PHARMALABS LIMITED JEEVAN MONDKAR COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565